Tyramine and octopamine independently inhibit serotonin-stimulated aversive behaviors in Caenorhabditis elegans through two novel amine receptors.
Biogenic amines modulate key behaviors in both vertebrates and invertebrates. In Caenorhabditis elegans, tyramine (TA) and octopamine (OA) inhibit aversive responses to 100%, but not dilute (30%) octanol. TA and OA also abolish food- and serotonin-dependent increases in responses to dilute octanol in wild-type but not tyra-3(ok325) and f14d12.6(ok371) null animals, respectively, suggesting that TA and OA modulated responses to dilute octanol are mediated by separate, previously uncharacterized, G-protein-coupled receptors. TA and OA are high-affinity ligands for TYRA-3 and F14D12.6, respectively, based on their pharmacological characterization after heterologous expression. f14d12.6::gfp is expressed in the ASHs, the neurons responsible for sensitivity to dilute octanol, and the sra-6-dependent expression of F14D12.6 in the ASHs is sufficient to rescue OA sensitivity in f14d12.6(ok371) null animals. In contrast, tyra-3::gfp appears not to be expressed in the ASHs, but instead in other neurons, including the dopaminergic CEP/ADEs. However, although dopamine (DA) also inhibits 5-HT-dependent responses to dilute octanol, TA still inhibits in dop-2; dop-1; dop-3 animals that do not respond to DA and cat-2(tm346) and Pdat-1::ICE animals that lack significant dopaminergic signaling, suggesting that DA is not an intermediate in TA inhibition. Finally, responses to TA and OA selectively desensitize after preexposure to the amines. Our data suggest that although tyraminergic and octopaminergic signaling yield identical phenotypes in these olfactory assays, they act independently through distinct receptors to modulate the ASH-mediated locomotory circuit and that C. elegans is a useful model to study the aminergic modulation of sensory-mediated locomotory behaviors.
Wragg
Rachel T
RT
Department of Biological Sciences, University of Toledo, Toledo, Ohio 43606-3340, USA.
Hapiak
Vera
V
Miller
Sarah B
SB
Harris
Gareth P
GP
Gray
John
J
Komuniecki
Patricia R
PR
Komuniecki
Richard W
RW
D000818:Animals; D001522:Behavior, Animal / Q000502:physiology*; D016466:CHO Cells; D019556:COS Cells; D017173:Caenorhabditis elegans; D029742:Caenorhabditis elegans Proteins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D002522:Chlorocebus aethiops; D006224:Cricetinae; D003412:Cricetulus; D006801:Humans; D051379:Mice; D041681:NIH 3T3 Cells; D009655:Octopamine / Q000494:pharmacology / Q000502:physiology*; D010802:Phylogeny; D017982:Receptors, Biogenic Amine / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology / Q000502:physiology*; D014439:Tyramine / Q000494:pharmacology / Q000502:physiology*
D029742:Caenorhabditis elegans Proteins; D017982:Receptors, Biogenic Amine; D009655:Octopamine; D012701:Serotonin; D014439:Tyramine